{
    "2020-09-01": [
        [
            {
                "time": "2023-10-05",
                "original_text": "House Panel Investigating Drug Prices To Subpoena AbbVie",
                "features": {
                    "keywords": [
                        "House Panel",
                        "Drug Prices",
                        "Subpoena",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "AbbVie 'Surprised, Disappointed' by House Panel Subpoena Plan",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Surprised",
                        "Disappointed",
                        "House Panel",
                        "Subpoena"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe",
                "features": {
                    "keywords": [
                        "U.S. House Oversight Committee",
                        "subpoena",
                        "AbbVie",
                        "drug-pricing",
                        "probe"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Forget Johnson & Johnson, AbbVie Is a Better Dividend Stock",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "AbbVie",
                        "Better Dividend Stock"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}